BCL6 and diffuse large B-cell lymphoma: The findings in this study for a group of DLBCL patients treated with R-CHOP suggest that patients with concurrent MYC/BCL6 rearrangements do not have a poorer prognosis and that grouping these tumors with other forms of DHL could lead to inappropriate therapy.